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Dendritic cells (DCs) are professional antigen presenting cells (APCs) that play a critical role 
in bridging innate and adaptive immunity.  Numerous studies have shown that tobacco 
constituents present in conventional cigarettes affect the phenotype and function of DCs; 
however, no studies have examined the effects of vapour from E-cigarettes on human DCs. 
Here the effects of E-cigarette vapour extract (ECVE) on the phenotype and function of DCs 
by creating an in vitro cell culture model using human monocyte-derived DCs (MoDCs) were 
investigated.  Immature DCs were generated from peripheral blood monocytes and mature DCs 
were then produced by treatment with LPS or Poly I:C for 24 hours.  For LPS-matured DCs, 
3% ECVE treatment slightly suppressed HLA-DR and CD86 expression, whereas 1% ECVE 
treatment enhanced IL-6 production.  The overall expression of 29 signalling molecules and 
other cytoplasmic proteins (mainly associated with DC activation) was significantly 
upregulated in immature DCs by 1% ECVE, and in LPS-treated DCs by 3% ECVE.  In 
particular, the condition that induced IL-6 production also upregulated MAPK pathway 
activation.  These findings indicate that E-cigarette vapour moderately affects human DCs, but 
the effects are less pronounced than those reported for tobacco smoke. 
 






































































Electronic cigarettes (E-cigarettes) are handheld electronic devices that generate 
vapours or aerosols by heating E-liquid. The main components of E-liquids are humectants (i.e. 
propylene glycol (PG), vegetable glycerol (VG)), nicotine and flavourings. E-liquid is stored 
in the cartridge and then supplied to the atomizer which contains a small coil of electrically 
resistant wire that heats up when the battery is switched on. E-cigarettes have gained rapidly 
in popularity around the world in recent years; sales of E-cigarettes are predicted to reach $44 
billion by 2023 (Research_and_Markets 2018). Since E-cigarettes were invented in 2003, their 
usage has increased dramatically:  in 2018, overall usage by adults in the USA was 7.6%, but 
this increases to 36.5% in ex-cigarette smokers (Dai and Leventhal 2019); amongst adolescents 
(16-19 years) in the USA, UK and Canada, between 32% and 37% used e-cigarettes in 2018 
(Hammond et al. 2019). In some countries E-cigarettes are promoted as a tool for smoking 
cessation (Beard et al. 2016; Etter 2010; Polosa et al. 2011; Polosa et al. 2014) and as a safe 
alternative to conventional cigarettes due to lower levels of carcinogens and toxicants in 
vapours (Goniewicz et al. 2014). However, the use of E-cigarettes remains controversial (Bush 
et al. 2019). A rapid rise in E-cigarette use has occurred not only amongst current smokers, but 
also non-smokers who may therefore develop a smoking habit and/or nicotine addiction (Lam 
et al. 2014).  Although it is still too soon to know the effects of chronic E-cigarette use over a 
period of decades, there have been several reports since 2014 of acute lung injury, pneumonitis 
and/or pneumonia associated with E-cigarette use (Arter et al. 2019; Khan et al. 2018; Layden 
et al. 2019; Moore K 2015; Nair et al. 2019; Sommerfeld et al. 2018; Thota and Latham 2014).   
E-cigarettes have been found to have effects on a variety of cell types in humans, 
including epithelial and endothelial cells, fibroblasts, macrophages and neutrophils (Chen et 
al. 2019).  However, the effects of E-cigarette vapours (ECV) on human myeloid DCs 
(mDCs) have not been studied previously.  By contrast, numerous studies have shown that 
the phenotype and functions of mDCs are affected by tobacco smoke, with suppression of T 
cell-stimulating, immunogenic properties of mDCs by CS constituents (Stampfli and 
Anderson 2009). Evidence for this derives from human and murine in vivo and in vitro 
studies. In a mouse smoking model, DCs show low expression of co-stimulatory molecules 
and reduced stimulation T cells (Robbins et al. 2004; Robbins et al. 2008). Similarly, in 
humans, smoking impairs the maturation of mDCs in the lungs, evidenced by reduced 



































































Treatment of mouse bone marrow-derived DCs (bmDCs) with cigarette smoke extract (CSE) 
differentially affects T cell stimulation, depending on T cell phenotype (CD4+ or CD8+) 
(Mortaz et al. 2009) and length of treatment (chronic exposure to CSE suppresses DC 
maturation) (Givi et al. 2015). The maturation of human monocyte-derived DCs (moDCs), 
and their ability to stimulate Th1 and Th17 cells, is also suppressed by CSE (Kroening et al. 
2008; Le Rouzic et al. 2016; Vassallo et al. 2005).  We have shown that CSE treatment of 
human moDCs reduced their expression of pro-inflammatory signalling molecules 
(Alkhattabi et al. 2018).  Although numerous chemicals within CS affect immune cells 
(Stampfli and Anderson 2009), nicotine is the main addictive component and has well-
documented suppressive effects on IL-12 production and Th1 stimulation by human moDCs 
and mouse bmDCs, promoting instead Th2 responses (Guinet et al. 2004; Nouri-Shirazi and 
Guinet 2003; Nouri-Shirazi and Guinet 2006; Nouri-Shirazi et al. 2007). Immunosuppressive 
effects of nicotine are exerted particularly via the α7 nicotinic acetylcholine receptor 
(Zdanowski et al. 2015).  It should also be noted that some studies indicate the activation of 
DCs by CS (Bratke et al. 2008; Vassallo et al. 2008; Vassallo et al. 2010).  
Although some studies have reported that CS and ECV have similar effects on various 
cell types (Chen et al. 2019), others have found that the effects of CS are much more 
pronounced and deleterious than those of ECV (Husari et al. 2016; Iskandar et al. 2019; 
Taylor et al. 2016).  Therefore, in view of the critical role of DCs in immunity and the 
marked effects of CS on DCs, in the current study the effects of ECV on the phenotype and 
function of DCs by creating an in vitro cell culture model using human moDCs was 
investigated. Human moDCs were treated with E-cigarette vapour extract (ECVE) and the 
effects of ECVE on surface marker expression, cytokine secretion and signalling pathways 
was examined. 
 
Materials and methods 
Generation of monocyte-derived DCs 
Fresh venous blood was taken into heparinised Vacutainer tubes from healthy, never-smoking 
volunteers with ethical approval (FMHS REC ref: 121-1706) and informed consent. Peripheral 
blood mononuclear cells (PBMCs) were separated by density gradient centrifugation using 



































































in RPMI complete medium, that is RPMI-1640 medium supplemented with 100 g/ml 
Penicillin-Streptomycin (Sigma-Aldrich, Gillingham, UK), 2mM L-Glutamine (Sigma-
Aldrich, Gillingham, UK), 10mM HEPES (Sigma-Aldrich, Gillingham, UK) and 10% fetal 
bovine serum (FBS, Sigma-Aldrich, Gillingham, UK).  
CD14+ monocytes were isolated from PBMCs using CD14+ microbeads (Miltenyi 
Biotec, Bisley, UK) by positive selection according to the manufacturer’s instructions. One ml 
of CD14+ cell suspension (5x105 cells) was added to each well in a 24-well plate (Costar, High 
Wycombe, UK) in the presence of 50 ng/ml GM-CSF (Peprotech, London, UK) and 400 IU 
IL-4 (Peprotech, London, UK) and incubated at 37℃, 5% CO2 for five days. Fresh medium 
and cytokines were added on day three.  To generate mature DCs, immature DCs on day five 
were stimulated with 100 ng/ml LPS or 30 g/ml Poly I:C (Sigma-Aldrich, Gillingham, UK) 
for 24 h. 
 
ECVE preparation  
E-cigarette devices and a DIY E-liquid Mixing Kit were purchased from VAPEMATE 
(Brentwood, UK). The E-liquid contained 50/50 PG/VG and 12 mg/ml nicotine. The smoking 
apparatus consisted of a three-way stopcock attached to a 50 ml syringe, the E-cigarette and a 
bottle containing 20 ml RPMI complete medium. The vapour was drawn into the syringe and 
then bubbled into the 20 ml RPMI complete medium at a flow rate of 50 mL/min. It took 
approximately 25 cycles to consume 200 mg of E-liquid. The medium was then filter-sterilized 
with a 0.45 m pore-size filter. The EC cartridge was weighed before and during the process 
to confirm that 200 mg of liquid was consumed. The resulting extract was considered as 100% 
ECVE. Further dilution was needed to generate 1% and 3% ECVE, which were used to treat 
DCs.  The choice of final ECVE concentrations was based on nicotine content as follows: the 
E-liquid contained 12mg of nicotine per gram of liquid. Therefore, 200mg of E-liquid 
contained 2.4 mg nicotine.  This resulted in 1% ECVE containing approximately 12 g/ml 
nicotine and 3% ECVE containing 36 g/ml nicotine.  This is similar to the nicotine 
concentrations in 0.5% to 3% cigarette smoke extract (CSE) used in previous studies 






































































Treatment of MoDCs with ECVE 
On Day 5, immature MoDCs were cultured with or without 100 ng/ml LPS (Sigma-Aldrich, 
Gillingham, UK), in the absence or presence of 1% or 3% ECVE, at 37℃, 5% CO2 for 24h.  
The cells treated with LPS or Poly I:C for 24h (with or without simultaneous treatment with 
ECVE) are referred to as ‘LPS-matured DCs’ or ‘Poly I:C-matured DCs’, respectively.   
 
Extracellular staining for surface marker detection 
DCs were placed in 1 ml PBA buffer (PBS, 1% BSA and 0.1% sodium azide) and centrifuged 
at 300 g for 5 minutes. The supernatant was discarded and the cell pellets were resuspended. 
Samples were incubated 30 minutes in the dark at room temperature with fluorochrome-
labelled antibodies (as indicated in Table 1); corresponding isotype control antibodies were 
also applied. After incubation, 2 ml of PBA was added to remove excess and unbound 
antibodies, followed by centrifugation at 300 g for 5 minutes. Finally, the cells were fixed with 
0.5% formaldehyde and the samples were kept at 4℃ until flow cytometric analysis. Flow 
cytometry was carried out using an FC500 Flow Cytometer (Beckman Coulter) and data was 
analysed using Weasel Software v3.0.2. 
 
Enzyme-linked immunosorbent assay (ELISA) for cytokine detection 
Cell-free culture supernatants were collected and stored at -20°C before analysis. The levels of 
cytokines IL-6, IL-8, IL-10, IL-12p70, and TNF- were measured by sandwich ELISA using 
Duo Set ELISA kits (R&D Systems) according to the manufacturer’s instructions.  
 
Reverse phase protein microarray (RPPA) 
RPPA was performed as described previously (Alkhattabi et al. 2018; Negm et al. 2014).  We 
had previously confirmed that the detection of signalling molecules by RPPA gave results 
consistent with those obtained by western blotting (Negm et al. 2014).  DCs were harvested 
and centrifuged for 5 minutes at 300 g. The pellets were resuspended in RIPA buffer (Thermo 



































































Scientific, Loughborough, UK) and benzonase nuclease ultrapure (Sigma-Aldrich, Gillingham, 
UK). Samples were then incubated on ice for 30 minutes with frequent shaking followed by 
centrifugation at 10,000 g at 4℃ for 10 minutes. The supernatants were collected and stored at 
-80℃ until assayed.  
Before conducting RPPA, a BCA protein assay was performed using a Micro BCA™ 
Protein Assay Kit (Thermo Scientific, Loughborough, UK) to confirm the protein 
concentration of lysates. Lysates were diluted to 500 g/ml with 4x SDS printing buffer 
containing 0.4M DTT and heated at 95 ℃ for 5 minutes. Subsequently, lysates were transferred 
to 394-well plates and were robotically spotted onto nitrocellulose-coated glass slides by 
microarrayer (MicroGrid II, Digilab) and dried in the air. Printed slides were stored at -20 ℃ 
until they were processed. 
Slides were incubated in Super G blocking buffer (Grace Bio-Labs) for 1 h. After 
washing with 0.5% Tween-20 in PBS 3 times for 5 minutes each time, slides were incubated 
with primary antibodies (Table 2) diluted in blocking buffer and incubated for 2 h at room 
temperature. Mouse anti--actin (Sigma Aldrich, Gillingham, UK), diluted 1:1000 in blocking 
buffer, was used to monitor this ‘housekeeping’ protein to control for differences in protein 
loading. After washing 3 times with 0.5 % Tween-20 in PBS, the slides were incubated with 
biotinylated secondary antibodies diluted 1:20,000 in blocking buffer and incubated for 2 h at 
room temperature. Next, the slides were incubated with streptavidin conjugated to infrared 
dyes, IRDYE-800CW (1:10,000 in blocking buffer, LI-COR Biotechnology, Cambridge, UK) 
for 30 minutes at room temperature. Lastly, the slides were rinsed with distilled water, 
centrifuged dry and scanned with a Licor Odyssey scanner (LI-COR Biotechnology, 
Cambridge, UK) at 800 nm. The resultant TIFF images were processed with GenePix Pro-6 
Microarray Image Analysis software (Molecular Devices). Protein signals were finally 
determined by using background subtraction and normalization to the internal housekeeping 
targets. 
Changes within the expression of many signalling molecules takes place within a few 
minutes of cell stimulation. In order to determine the peak of signalling molecule expression, 
a time course experiment was performed. DCs were treated with LPS and ECVE for the 
following time durations: 5, 15, 30, 60 and 120 minutes and expression of signalling molecules 
examined by RPPA. The expression of many signalling molecules peaked at 30 minutes, 



































































addition to 24h-ECVE treatment, 30 minute ECVE treatment was employed to the study the 
effects of ECVE treatment on signalling pathways in DCs. 
 
Statistical analysis 
Data were analysed using GraphPad Prism v7.02 for Windows (GraphPad Software) and values 
expressed as median from independent experiments, unless otherwise stated. A test for 
normality was performed and either paired t-test/Wilcoxon matched-pairs test or paired one-
way ANOVA/paired Friedman test was performed, as appropriate to the data. A p value <0.05 
was considered statistically significant. 
 
Results 
The effects of ECVE on surface markers of MoDCs 
The generation of mature DCs by treatment of MoDCs with LPS was confirmed by changes in 
surface markers expression using flow cytometry.  Stimulation of MoDCs with 100 ng/ml LPS 
for 24 hours significantly elevated surface expression of HLA-DR, CD80, CD86, CD40, CD83, 
PD-L1 and CXCR4, but decreased expression of DC-SIGN (Figure 1). 
To determine the effect of ECVE on surface marker expression, immature and LPS-
matured DCs were treated with or without ECVE for 24 h (Figures 2 and 3 respectively); ECVE 
treatment did not significantly reduce the viability of moDCs (data not shown).  The expression 
of CD83 on immature DCs was slightly, but significantly reduced after 3% ECVE treatment 
for 24 h (Figure 2). Treatment with 3% ECVE slightly, but significantly, inhibited the 
expression of HLA-DR and CD86 on LPS-matured DCs (Figure 3).  No alterations were found 
in the expression of other surface markers in response to ECVE treatment.  
Stimulation of MoDCs with 30g/ml Poly I:C for 24 hours also significantly elevated 
surface expression of HLA-DR, CD80, CD86, CD40, CD83 and PD-L1 (but not CXCR4), and 
decreased expression of DC-SIGN (Supplementary Figure 1S).  The treatment of Poly I:C-
matured DCs with 1% or 3% ECVE did not alter significantly the expression of any of the 




































































The effects of ECVE on cytokine production by MoDCs 
The culture supernatants of immature and LPS-matured DCs, cultured in the absence or 
presence of 1% or 3% ECVE for 24 hours, were assayed by ELISA to determine levels of IL-
6, IL-8, IL-10, IL-12p40 and TNF-.  Twenty-four hour ECVE treatment did not affect the 
secretion of these cytokines from immature DCs. For LPS-matured DCs, 1% (but not 3%)       
ECVE significantly enhanced the production of IL-6 (Figure 4).  Levels of IL-8, IL-10, IL-
12p70 and TNF- were unaffected by ECVE treatment.  
 The treatment of Poly I:C matured DCs with 1% or 3% ECVE for 24 h did not 
significantly alter secreted levels of any of the cytokines assayed (IL-6, IL-8, IL-10, IL-12p70 
or TNF-) (Supplementary Figure 3S).   
   
The effects of ECVE on signalling molecule expression of MoDCs 
RPPA was used to analyse the expression by DCs of 29 signalling molecules and other 
cytoplasmic molecules mainly associated with DC activation and immunogenicity; several of 
the molecules are involved in IRAK/IRF, MAPK, NF-B, JAK/STAT and PI3K/AKT 
pathways, amongst others (see Table 2). Thirty-minute or 24h ECVE treatment did not cause 
a statistically significant change in the expression of most individual molecules of immature, 
LPS-matured or Poly I:C-matured DCs (data not shown).  However, it was observed that, for 
many molecules, ECVE treatment gave a trend towards higher molecule expression. We 
therefore determined the combined or ‘global’ effects of ECVE on all 29 molecules 
investigated by comparing the median expression (for up to 9 donors) of all molecules in the 
absence or presence of ECVE.  The basis for this is that biological effects are likely to depend 
on the cumulative changes in expression of multiple molecules associated with signalling 
pathways, although the change for each individual molecule may be relatively subtle. 1% 
ECVE treatment was then seen to increase significantly the global expression of the molecules 
in immature DCs after 30 minutes (Figure 5A) and 24h (Figure 5B). 3% ECVE treatment also 
significantly increased global expression of the molecules in LPS-maturing DCs after 30 
minutes (Figure 5A) and in LPS-matured DCs after 24 h (Figure 5B).  
 For Poly I:C-treated DCs, 1% ECVE treatment for 30 minutes significantly reduced the 



































































3% ECVE for 30 minutes, or either 1% or 3% ECVE for 24 hours had no significant effect on 
global signalling molecule expression (Supplementary Figure 4S). 
We observed that many of the molecules upregulated by 24h treatment of LPS-matured 
DCs with 1% ECVE (i.e. the conditions in which ECVE treatment significantly enhanced IL-
6 production) were those associated with the IRAK/TRAF6/TAB pathway that is stimulated 
when LPS binds to TLR4, and which leads to MAPK activation and IL-6 production: these 
molecules are IRAK1, IRAK2, TAB2, pTAB2, pP38, pERK1/2 and pC-Fos (figure 6i).  In 
addition, the molecules HMGB1 and SOD1, which can further stimulate this pathway are 
presented (Figure 6i).  Conversely, certain molecules that were also measured can have an 
inhibitory effect on the pathway (i.e. IRAK-M, pSTAT-3, pMST-1) (Figure 6ii).  The median 
values for all of these molecules (from up to 9 donors) are plotted: this shows that both 1% 
ECVE (figure 6i, left panel) and 3% ECVE (figure 6i, right panel) significantly up-regulated 
the signalling (and other) molecules associated with the IRAK/TAB/MAPK inflammatory 
pathway.  However, whereas 1% ECVE treatment did not upregulate the inhibitory molecules 
IRAK-M and pSTAT3 (figure 6ii, left panel), 3% ECVE treatment did upregulate these 
inhibitory molecules (figure 6ii, right panel).  This may explain why IL-6 production by LPS-
matured DCs is upregulated by treatment with 1% ECVE, but not with 3% ECVE.   
    
Discussion 
The effects of E-cigarettes on the human immune system are not fully elucidated; in particular, 
the effects of ECVE on human DCs have not been investigated previously although numerous 
studies have shown deleterious (and mainly immunosuppressive) effects of CS on DCs 
(Alkhattabi et al. 2018; Arellano-Orden et al. 2016; Givi et al. 2016; Guinet et al. 2004; 
Kroening et al. 2008; Le Rouzic et al. 2016; Liao et al. 2015; Mortaz et al. 2009; Nouri-Shirazi 
and Guinet 2003; Nouri-Shirazi and Guinet 2006; Nouri-Shirazi et al. 2007; Robbins et al. 
2004; Robbins et al. 2008; Stampfli and Anderson 2009; Vassallo et al. 2005). DCs are 
professional antigen presenting cells that link innate and adaptive immunity; therefore, due to 
the importance of DCs within the immune system, the aim of the present study was to 
investigate the effects of ECVE on the biological behaviour of DCs in vitro using human 



































































The present study showed that ECVE treatment of DCs slightly reduced the expression 
of some surface markers, but enhanced the production of the pro-inflammatory cytokine IL-6 
by LPS-matured DCs.  The ECVE treatment of immature and LPS-matured DCs also broadly 
upregulated their expression of signalling molecules (and other cytoplasmic molecules) 
associated with DC activation.  Interestingly, ECVE did not upregulate IL-6 production by 
Poly I:C-matured DCs, nor enhance their signalling molecule expression.  In fact, short-term 
exposure to 1% ECVE of Poly I:C-treated DCs down-regulated signalling molecule expression. 
It thus appears that ECVE can have different effects on DCs depending on which toll-like 
receptor (TLR) pathways are also stimulated (i.e. TLR-4 by LPS and TLR-3 by Poly I:C).  This 
also relates to the type of infection that may be a co-factor, i.e. bacterial (LPS) or viral (Poly 
I:C). 
Compared to the numerous previous reports of the effects of CS on DCs (including our 
own using the same experimental conditions employed here (Alkhattabi et al. 2018)), the 
present study indicates that ECVE has less pronounced effects than CS on DCs.  This is 
consistent with some other studies that have compared the effects of CS and ECV on different 
cell types.  In particular, Iskandar et al. (Iskandar et al. 2019) recently reported that, in a multi-
layer toxicology system, E-liquid and E-vapour were less toxic to cultured airway epithelial 
cells than was CS.  They found that the ‘Base’ E-liquid that is equivalent to that used in our 
study (containing the humectants propylene glycol and vegetable glycerin, plus nicotine), and 
MESH Classic Tobacco-flavoured E-liquid, showed similar levels of toxicity.  Thus, this 
particular flavouring showed no additional toxicity over the Base E-liquid.  However, more 
than 8000 different E-liquid flavourings are now available and it is probable that at least some 
of these will have significant respiratory and/or systemic toxicity.  Indeed, some of these 
flavourings may be responsible for the cases of E-cigarette induced hypersensitivity 
pneumonitis and other lung-damaging reactions that have been reported (e.g. (Nair et al. 
2019)).  Some flavourings have been shown to induce alterations in various cell types, 
including affecting their viability, proliferation, phagocytic ability and cytokine production 
(Chen et al. 2019). It would there be of interest to use flavoured E-liquids to generate ECVE 
and evaluate their effects on DCs. 
A specific point of consistency between the effects of Base ECV on human immature 
and LPS-matured MoDCs in the present study, and on buccal epithelial cells in the study of 
Iskandar et al. (Iskandar et al. 2019) is that we observed upregulation of inflammatory 



































































an inflammatory transcriptome at 4 h and 24 h.  In addition, we observed upregulation by ECVE 
of the release of IL-6 (but not other cytokines) from LPS-matured DCs, and they observed 
increased release of IL-1 and IP-10 (but not other cytokines) by buccal cells in response to 
Base ECV.  These different studies thus provide consistent evidence for mild pro-inflammatory 
effects of Base ECV. 
Treatment of DCs with 3% ECVE slightly, but significantly, inhibited surface 
expression of HLA-DR and CD86 in LPS-matured DCs. HLA-DR is an MHC II molecule that 
provides ‘signal 1’ in DC-T cell interaction.  The co-stimulatory molecules CD80 and CD86 
deliver the ‘signal 2’ to T cells: these bind to the CD28 molecule on T cells, thereby promoting 
their activation. Upregulation of co-stimulatory molecule levels is characteristic of mature 
DCs, as seen in the current study when stimulating immature DCs with LPS. Interestingly, we 
found that 3% ECVE attenuated CD86 expression on LPS-matured DCs, but not CD80 
expression. The expression of CD80 is more abundant than CD86 on immature DCs while 
CD86 expression increases more rapidly and strongly than CD80 in response to stimuli that 
induce DC maturation (Sansom et al. 2003). Although both CD80 and CD86 can bind to CD28, 
CD80 in particular also interacts with CTLA-4 (Sansom et al. 2003) which inhibits T cell 
activation and proliferation (Krummel and Allison 1996). Compared to CD80, CD86 is a more 
important co-stimulatory molecule for T cell activation (Sharpe 1995) and blockade of CD86 
has been reported to inhibit T cell proliferation in mixed lymphocyte reactions (Ke et al. 2016; 
Zheng et al. 2004), whereas blockade of CD80 promoted it (Zheng et al. 2004). In the current 
study, levels of CD86 but not CD80 were slightly decreased by 3% ECVE in LPS-matured 
DCs suggesting a potential role of this higher dose of ECVE in attenuating T cell activation by 
DCs. 
Numerous studies have reported evidence of a role for IL-6 in inflammatory lung 
diseases, including hypersensitivity pneumonitis (Denis et al. 1992; Moodley et al. 2003; Park 
et al. 2000; Schuyler et al. 2000; Shieh et al. 2019). Several studies show that CS enhances IL-
6 production by various types of cells including DCs (Chi et al. 2012; Givi et al. 2015; Wang 
et al. 2017), and in BALF of mice (Givi et al. 2016). In the current study, 1% ECVE 
significantly stimulated IL-6 secretion by LPS-matured DCs, suggesting E-cigarette use may 
promote an inflammatory environment in humans. However, the levels of other cytokines 
including IL-8, IL-10, IL-12 and TNF-remained unchanged after ECVE treatment, although 
it has been reported that they are altered by CS treatment of DCs (Givi et al. 2016; Givi et al. 



































































condensate enhanced production of IL-6 by human alveolar macrophages (Scott et al. 2018), 
consistent with our findings reported here for human DCs.  However, E-cigarette vapour 
condensate also enhanced the production of TNF-, CXCL-8 (IL-8), MCP-1 and MMP-9 by 
alveolar macrophages (Scott et al. 2018).  These different findings may be partly due to the 
different cell types being studied (i.e. alveolar macrophages versus monocyte-derived DCs) 
and/or the different methods of producing E-cigarette vapour extract or condensate. 
Compared with other proteomic methods, RPPA is a sensitive and high-throughput 
technology which yields a large volume of quantitative or semi-quantitative molecular 
information in an experiment using only nanolitres of sample (Mueller et al. 2010).  In the 
present study, the effects of ECVE treatment of DCs on the expression of individual signaling 
molecules was relatively subtle and, for most individual molecules, not statistically significant.  
However, as we have noted in other systems examined in this way (Negm et al. 2014), although 
effects on individual signalling molecules may seem relatively small, the combined or ‘global’ 
effects on multiple signalling molecules may be both statistically and biologically significant. 
Thus, looking at the global effects of ECVE, 1% ECVE generally enhanced expression of the 
signalling molecules at both 30 minutes and 24 hour in immature DCs.  For LPS-treated DCs, 
3% ECVE significantly enhanced the expression of the signalling molecules at both 30 minutes 
and 24 h, suggesting up-regulation of signalling molecule expression as also seen in immature 
DCs, but with different sensitivity to ECVE concentration.  By contrast, we found that 30 
minute treatment with 1% ECVE suppressed signalling molecule expression by Poly I:C-
stimulated DCs, as we previously reported for the effects of CSE and nicotine (Alkhattabi et 
al. 2018). 
Some signalling molecules have inhibitory/regulatory activities rather than 
activating/inflammatory activities in particular contexts.  We thus observed that the conditions 
that promoted IL-6 production by DCs (i.e. 1% ECVE-treatment of LPS-matured DCs) did not 
give an overall statistically significant enhancement of all 29 molecules detected by RPPA at 
the ‘global’ level.  However, these conditions did significantly upregulate molecules involved 
in the IRAK/TAB/MAPK inflammatory pathway, but did not upregulate certain molecules that 
can be inhibitory, in particular IRAK-M (Kobayashi et al. 2002) and pSTAT3 (Zhang et al. 
2014) (see figure 7).  Since the MAPK pathway is involved in maturation (Bansal et al. 2010; 
Dunand-Sauthier et al. 2011b; Nakahara et al. 2004; Pathak et al. 2012), cytokine production 
(Dunand-Sauthier et al. 2011a; Nakahara et al. 2004) and antigen-specific T cell activation 



































































induced by ECVE may enhance functionality of DCs. By contrast, 3% ECVE-treatment of 
LPS-matured DCs significantly upregulated all 29 molecules, including IRAK-M and pSTAT-
3, which may explain why 3% ECVE treatment did not enhance IL-6 production.  Interestingly, 
ECVE treatment did not consistently upregulate signalling molecules associated with the NFB 
pathway (cRel and pP65), again indicating that the increased IL-6 production in response to 
ECVE plus LPS was probably stimulated via the MAPK pathway.  We also observed that 
ECVE treatment upregulated DC expression of HMGB1 and SOD1: the former promotes 
TLR4 signalling (Bianchi 2009; Park et al. 2006) and DC maturation (Messmer et al. 2004), 
and the latter promotes MAPK activity via production of hydrogen peroxide (Wang et al. 
2018).   Overall, the global enhancement in expression of the inflammatory signalling 
molecules and other cytoplasmic molecules in DCs by ECVE treatment would be consistent 
with ECVE promoting DC functions and activity.   
In conclusion, this study established an in-vitro model to investigate the effects of 
ECVE on human monocyte-derived DCs. Several biological aspects of DCs have been 
examined including signalling pathways, surface markers and cytokine production, using a 
variety of culture conditions. ECVE generally had moderate effects on DC function, including 
changed levels of signalling molecules and production of the pro-inflammatory cytokine IL-6. 
Therefore, E-cigarettes are not completely harmless to human DCs, but the effects appear to 
be less pronounced than those reported for CS.  
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Antibody Clone Isotype Fluorochrome Company 
CD80 IM1853U IgG1 FITC Beckman Coulter 
DC-SIGN A07407 IgG1 PE Beckman Coulter 
CD86 REA968 IgG1 FITC Miltenyi Biotec  
CD83 REA714 IgG1 PE Miltenyi Biotec  
HLA-DR REA805 IgG1 APC Miltenyi Biotec  
CD40 REA733 IgG1 PE-Vio 770 Miltenyi Biotec  
CD36 REA760 IgG1 FITC Miltenyi Biotec  
CXCR-4 REA649 IgG1 APC Miltenyi Biotec  
CD74 REA1103 IgG1 PE-Vio 770 Miltenyi Biotec  




































































Table 2. Primary antibodies used in RPPA specific for the proteins of interest in DC 
lysates.  All antibodies were purchased from Cell Signalling Technology  
Antibody 
Specificity 

















































































































































Figure 1. Comparison of MFI value of surface markers between untreated immature and 
LPS-matured DCs. Data is presented as scatter plots and each dot represents a different 
individual donor. The median of six independent experiments is shown. If data was normally 
distributed, paired t-test was used, otherwise Wilcoxon test was used.  * p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
 
Figure 2. The MFI of surface markers on immature DCs after 24 h with or without ECVE 
treatment. Data is presented as scatter plots and each dot represents a different individual 
donor. The median of six individual experiments is shown. If data was normally distributed, 
paired one-way ANOVA was used, otherwise paired Friedman test was used.   
 
Figure 3. The MFI of surface markers on LPS-matured DCs after 24 h with or without 
ECVE treatment. Data is presented as scatter plots and each dot represents a different 
individual donor. The median of six individual experiments is shown. If data was normally 
distributed, paired one-way ANOVA was used, otherwise paired Friedman test was used.   
 
Figure 4.  Cytokine production by immature and LPS-matured DCs after 24 h with or 
without ECVE treatment. Data is presented as scatter plots of eight independent experiments 
and their medians. If data was normally distributed, paired one-way ANOVA was used, 
otherwise paired Friedman test was used.  
 
Figure 5. The effects of ECVE-treatment on global expression of signalling molecules by 
DCs. Global effects on 29 signalling molecules in DCs treated with ECVE for (A) 30 minutes 
and (B) 24h.  Data is presented as scatter plots and each dot represents the median expression 
of each signalling molecule from up to nine independent experiments. If data were normally 





































































Figure 6. Selected RPPA data for LPS-matured DCs treated with 1% or 3% ECVE.  The 
median values presented are taken from figure 5.   Data is presented as scatter plots and each 
dot represents the median expression of each signalling molecule from up to nine independent 
experiments. If data were normally distributed, paired-t test was used; otherwise Wilcoxon test 
was used.  In fig. 6i: for 0% versus 1% ECVE, p = 0.0085; for 0% versus 3% ECVE, p < 
0.0001. 
 
Figure 7.  Schematic representation of the LPS-TLR4 MAPK pathway stimulated by 
1% ECVE treatment of LPS-matured MoDCs.  (Based on data presented in figure 6.)  
Molecules that were found to be upregulated by 1% ECVE treatment are shown in red.  
Molecules that were unchanged or down-regulated by 1% ECVE treatment are shown in 
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